<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954692</url>
  </required_header>
  <id_info>
    <org_study_id>GLARGL07921</org_study_id>
    <secondary_id>U1111-1183-8755</secondary_id>
    <nct_id>NCT02954692</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey</brief_title>
  <acronym>EASE</acronym>
  <official_title>A National, Multicenter, Prospective, Interventional, Open-label, Single-arm, 24-Week Phase IV Study to Evaluate the Effectiveness and Safety of Initiation and Titration of Insulin Glargine U300 in Insulin-naïve Patients With T2DM Inadequately Controlled on OAD Treatment in Turkey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the mean change in HbA1c (glycated haemoglobin).

      Secondary Objectives:

      To evaluate the efficacy and safety of the titration of insulin glargine U300 in terms of:

        -  Targeted HbA1c;

        -  Targeted fasting self- monitoring blood glucose (SMBG);

        -  Hypoglycemic events;

        -  Adverse events;

        -  Quality of life assessment by DTSQs (Diabetes Treatment Satisfaction Questionnaire
           status) and DTSQc (Diabetes Treatment Satisfaction Questionnaire change);

        -  Blood glucose fluctuation by using continuous glucose monitoring system (CGMS) in
           subgroup patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per patient will be 27 weeks (2 weeks of screening, 24 weeks on
      treatment, and 1 week follow-up period).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 30, 2016</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in HbA1c</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving targeted fasting self-monitored blood glucose (SMBG) without experiencing severe and/or confirmed hypoglycemia ≤70mg/dL and &lt;54 mg/dL</measure>
    <time_frame>At Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching targeted fasting SMBG (80-130 mg/dL)</measure>
    <time_frame>At Weeks 12 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration to reach target pre-breakfast SMBG</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HbA1c</measure>
    <time_frame>Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in SMBG</measure>
    <time_frame>Baseline, Weeks 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline, Weeks 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Diabetes Treatment Satisfaction Questionnaire (DTSO) scores</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin glargine (U300) will be administered daily through subcutaneous injection, and thereafter, dose will be titrated weekly (preferably 3-4 days) as needed. Background non-insulin anti-diabetic drugs approved for use in combination with insulin according to local labelling, will be permitted, with the exception of Thiazolidinediones (TZDs), which must be stopped at the time of basal insulin initiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE (U300)</intervention_name>
    <description>Pharmaceutical form: pen for injection
Route of administration: subcutaneous</description>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
    <other_name>HOE901</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulfonylurea</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meglitinides</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiazolidinediones</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-glucosidase inhibitors</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP1 Receptor Agonist</intervention_name>
    <description>Pharmaceutical form: pen for injection
Route of administration: subcutaneous</description>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dipeptidyl peptidase-IV (DPP-IV) inhibitors</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium-glucose transport-2 (SGLT-2) inhibitors</intervention_name>
    <description>Pharmaceutical form: tablet
Route of administration: oral</description>
    <arm_group_label>Insulin glargine (U300)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Adult patients with type 2 diabetes mellitus (≥18 years of age).

          -  Type 2 diabetes mellitus diagnosis ≥1 year.

          -  Treated with ≥1 oral antidiabetics (±glucagon like peptid-1 (GLP-1) analogue) without
             insulin, for at least 6 months and HbA1c level between 8-11% (insulin-naïve).

          -  Stable antidiabetic treatment for at least 3 months.

          -  Willingness to adherence to treatment and titration (including self-injection, self-
             monitoring blood glucose [SMBG]).

          -  Signed informed consent obtained.

        Exclusion criteria:

          -  Age &lt;18 years old.

          -  Type 1 diabetes mellitus.

          -  Having secondary type 2 diabetes mellitus.

          -  Use of any insulin therapy including premix, basal plus/basal bolus regimen from the
             diagnosis.

          -  History of hypoglycemia unawareness.

          -  Known hypersensitivity/intolerance to insulin glargine or any of its excipients.

          -  Have any condition (including known substance or alcohol abuse or psychiatric
             disorder) that precludes the patient from following and completing the study protocol.

          -  Use of systemic glucocorticoids for two weeks or more within 12 weeks prior to the
             time of screening.

          -  Pregnant or lactating women.

          -  Participation in another clinical trial.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Turkey</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>2,4-thiazolidinedione</mesh_term>
    <mesh_term>Meglitinide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

